The UAE has become the second country in the world to approve the new lung cancer drug 'Lumakras'.
The Ministry of Health and Prevention (MoHAP) has cleared the registration and use of the drug, which recently received the approval of the US Food and Drug Administration (FDA).
It will help speed up the treatment plan of patients in the UAE and improve their quality of life.
Lumakras, manufactured by Amgen, is prescribed to adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received at least one previous cancer therapy.
It is supplied as film-coated tablets for oral use containing 120 mg of sotorasib.
H.H. Sheikh Mohammed to fund life-saving treatment for Jordanian girl
Two convicted in Al Ain for assaulting a petrol station employee
UAE approves review fee structure for higher education sector
Abu Dhabi records first-ever Olive Ridley turtle nest
National University of Dubai appoints inaugural President
UAE takes action over social media post insulting Emirati women
Sheikh Abdullah congratulates Colombian FM on appointment
Discover Abu Dhabi Festival takes Emirati culture to Moscow
